Form 4: Terns Pharmaceuticals Director Acquires 64,000 Stock Options

Heather D Turner, a director at Terns Pharmaceuticals, acquired 64,000 stock options on November 18, 2024.

Summary

• Heather D Turner, a director of Terns Pharmaceuticals, acquired 64,000 stock options on November 18, 2024.
• The options have an exercise price of $5.70.
• The options vest over three years, with one-third vesting on the first anniversary of November 18, 2024, and the remainder vesting monthly thereafter.
• The options expire on November 17, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director has a vested interest in the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry, used to align the interests of management with those of shareholders.
• The vesting schedule of one-third after one year and the remainder monthly over the next two years is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, insider trading, director, Terns Pharmaceuticals, equity, vesting